"Once again, it's not the K Factor that's killing the abnormal cells," Yang Ping explained to everyone, "it's simply helping the system recognize the identity anomaly of these cells and then self-regulate. Some cells are adjusted to normal cells, while others, unable to reverse, are cleared by the system. The way K Therapy handles these precancerous lesions is essentially the same as its approach to cancer; it regulates. The role of the K Factor is to assist the system in regaining the ability to identify the real identities of these cells. Once it can recognize these cells' true identities, it can reverse or clear them to restore the body to normal."
Manstein said in the WeChat group, "A team from the NIH in the United States is reaching out to me. They are also researching early intervention for Lynch Syndrome, but their approach is entirely different—they are designing genetic editing tools to attempt to repair MSH2 mutations in somatic cells. What do you think?"
